Citations

Showing 10 of 108081 citations.

Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease
Schell, Trevor , Almasry, Mazen, Caldera, Freddy , Ramirez, Oscar Ramirez , Caldera, Freddy , Schell, Trevor L , Ramirez Ramirez, Oscar , Ramirez, Oscar, Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Inflammatory Bowel Diseases | April 18, 2023 | Volume: 29 | Issue: 10 | Pages: e38-e39

10.1093/ibd/izad068 | PMID 37071782 Get It

Three-Dimensional Structure of Inner Ear Hair Cell Ribbon Synapses in a Zebrafish Model of Usher Syndrome Type 1B
Riley, Kenneth C. , Riley, Kenneth C. , Koleilat, Alaa , Dugdale, Joseph , Cooper, Shawna A. , Christensen, Trace , Schimmenti, Lisa A. , Koleilat, Alaa , Dugdale, Joseph A , Cooper, Shawna A , Christensen, Trace A , Schimmenti, Lisa A

Mayo Clinic

Zebrafish | April 18, 2023 | Volume: 20 | Issue: 2 | Pages: 47-54

10.1089/zeb.2022.0049 | PMID 37071854 Get It

Our understanding of inner ear hair cell ultrastructure has heretofore relied upon two-dimensional imaging; however, serial block-face scanning electron microscopy (SBFSEM) changes this paradigm allowing for three-dimensional evaluation. We compared inner ear hair cells of the apical cristae in myo7aa −/− null zebrafish, a model of human Usher Syndrome type 1B, to hair cells in wild-type zebrafish by SBFSEM to investigate possible ribbon synapse ultrastructural differences. Previously, it has been shown that compared to wild type, myo7aa −/− zebrafish neuromast hair cells have fewer ribbon synapses yet similar ribbon areas. We expect the recapitulation of these results within the inner ear apical crista hair cells furthering the knowledge of three-dimensional ribbon synapse structure while resolving the feasibility of therapeutically targeting myo7aa −/− mutant ribbons. In this report, we evaluated ribbon synapse number, volume, surface area, and sphericity. Localization of ribbons and their distance from the nearest innervation were also evaluated. We determined that myo7aa −/− mutant ribbon synapses are smaller in volume and surface area; however, all other measurements were not significantly different from wild-type zebrafish. Because the ribbon synapses are nearly indistinguishable between the myo7aa −/− mutant and wild type, it suggests that the ribbons are structurally receptive, supporting that therapeutic intervention may be feasible.
Good’s Syndrome: Thymoma with Acquired Immunodeficiency
Koo, Chi Wan , Lo, Ying‐Chun

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 18, 2023 | Volume: 208 | Issue: 3 | Pages: 322-324

10.1164/rccm.202211-2159im | PMID 37071872 Get It

Clonally Selected Lines After CRISPR-Cas Editing Are Not Isogenic
Panda, Arijit , Mariani, Jessica , Jang, Yeongjun , Kollmeyer, Thomas M. , Sarkar, Gobinda , Kim, Ji‐Eun , Yoon, Wan Hee , Jenkins, Robert B. , Vaccarino, Flora M. , Abyzov, Alexej , Kollmeyer, Thomas , Vaccarino, Flora M , Abyzov, Alexej , Jang, Yeongjun , Šuvakov, Milovan , Drucker, Kristen , Park, Yohan , Bae, Taejeong

Mayo Clinic

The CRISPR Journal | April 18, 2023 | Volume: 6 | Issue: 2 | Pages: 176-182

10.1089/crispr.2022.0050 | PMID 37071670 Get It

The CRISPR-Cas9 system has enabled researchers to precisely modify/edit the sequence of a genome. A typical editing experiment consists of two steps: (1) editing cultured cells; (2) cell cloning and selection of clones with and without intended edit, presumed to be isogenic. The application of CRISPR-Cas9 system may result in off-target edits, whereas cloning will reveal culture-acquired mutations. We analyzed the extent of the former and the latter by whole genome sequencing in three experiments involving separate genomic loci and conducted by three independent laboratories. In all experiments we hardly found any off-target edits, whereas detecting hundreds to thousands of single nucleotide mutations unique to each clone after relatively short culture of 10–20 passages. Notably, clones also differed in copy number alterations (CNAs) that were several kb to several mb in size and represented the largest source of genomic divergence among clones. We suggest that screening of clones for mutations and CNAs acquired in culture is a necessary step to allow correct interpretation of DNA editing experiments. Furthermore, since culture associated mutations are inevitable, we propose that experiments involving derivation of clonal lines should compare a mix of multiple unedited lines and a mix of multiple edited lines.
The Adverse Effects Profile of Teprotumumab
Stan, Marius N. , Krieger, Christine C.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 18, 2023 | Volume: 108 | Issue: 9 | Pages: e654-e662

10.1210/clinem/dgad213 | PMID 37071658 Get It

Abstract Context Teprotumumab therapy for thyroid eye disease (TED) patients represents a major step forward. It targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), and its effectiveness is based on its interconnectedness with the thyrotropin receptor. However, IGF-1R has a ubiquitous expression and several adverse effects have been reported with teprotumumab use. Objective Describing these adverse effects for better understanding is the purpose of this review. Methods We reviewed the oncological studies in which teprotumumab was initially used. Subsequently we reviewed the clinical trials for TED and then the case series and case reports associated with teprotumumab use since it is US Food and Drug Administration approval (January 2020). We focused on common and/or serious adverse effects reported with the use of teprotumumab. Results We described the common occurrence of hyperglycemia (10%-30% incidence), its risk factors and suggested management. Hearing changes are described, a broad spectrum from mild ear pressure to hearing loss (sensorineural mechanism). Risk factors, suggested monitoring, and possible upcoming therapies are reviewed. We also reviewed data on fatigue, muscle spasms, hair loss, weight loss, gastrointestinal disturbances, menstrual changes, and infusion reactions. We noted some discrepancies between adverse effects in oncological studies vs studies focused on TED, and we aimed to explain these differences. Conclusion The use of teprotumumab should consider patient's values and preferences in balancing the expected benefit with these potential risks. Future drugs targeting IGF-1R should investigate these adverse effects for a possible class effect. Combination therapies with different agents hopefully will be identified that maximize benefits and minimize risks.
Invited Commentary: The Fate of MAPCAs
Cetta, Frank

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | April 18, 2023 | Volume: 14 | Issue: 3 | Pages: 273-274

10.1177/21501351231162913 | PMID 37071568 Get It

The safety profile of single antiplatelet therapy with flow diverters: Systematic review and meta-analysis
Şenol, Yiğit Can , Orscelik, Atakan , Ghozy, Sherief , Kobeissi, Hassan , Bilgin, Cem , Kadirvel, Ramanathan , Kallmes, David F. , Arul, Santhosh , Bilgin, Cem , Kadirvel, Ram , Kallmes, David F , Ghozy, Sherief , Kobeissi, Hassan , Orscelik, Atakan , Senol, Yigit Can

Mayo Clinic

Interventional Neuroradiology | April 18, 2023 | Volume: 32 | Issue: 3 | Pages: 732-740

10.1177/15910199231168669 | PMID 37071551 Get It

Background Dual antiplatelet therapy (DAPT) is frequently used in treating cerebral aneurysms with flow diverters (FDs), whereas single antiplatelet therapy (SAPT) is used mostly with coated FDs and in ruptured aneurysms. We conducted a systematic review and meta-analysis to explore the safety profile of SAPT in FDs. Methods PubMed, Web of Science, OVID Embase, OVID Medline, and Scopus were searched to 1st November 2022. Outcomes of interest included ischemic and hemorrhagic complications, conversion to DAPTs, and in-stent stenosis rates under long-term SAPT. SAPT is divided into aspirin (ASA) vs. non-ASA group (ticagrelor or prasugrel). Subgroup analysis was performed for ruptured vs. non-ruptured aneurysms and coated vs. non-coated FDs. All data were analyzed using R software version 4.2.2. Results Twelve studies with 240 total patients (43 patients in the ASA group and 197 patients in the non-ASA group) were included in our meta-analysis. The pooled ischemic occlusion rate was 9.8% (95% CI = 4.87−18.95: p-value = 0.09) for SAPTs. The ASA group had significantly higher ischemic complication rates compared to the non-ASA group (20.8% vs. 6.3%, respectively, p-value = 0.02). The pooled hemorrhagic complication rate was 3.5% (95% CI = 1.38−8.81: p-value > 0.99). The hemorrhagic rates of ASA group were 9.3%% (95% CI = 3.54−22.30) over the non-ASA group 2.1% (95% CI = 0.58−7.54) ( p-value > 0.99). The overall in-stent stenosis rate was 2.3% (95% CI = 1.06−5.14: p-value > 0.99). The ischemic complication rates were comparable between coated vs non-coated FDs (10.7% vs. 5.5% p-value = 0.39). In stent stenosis rate were 1.9% (95% CI = 0.72−4.96) in coated FDs over 4.4% (95% CI = 1.11−16.11) ( p-value = 0.32). The ruptured and non-ruptured groups also showed comparable results in terms of ischemic (17.6% vs. 7.1% respectively, p-value = 0.24) and hemorrhagic complications (9.8% vs. 1.1%, respectively, p-value = 0.08). Conclusions Flow diverter treatment under ASA monotherapy resulted in relatively high ischemic complication rates. However, SAPT with prasugrel or ticagrelor monotherapy is promising for coated FDs and ruptured aneurysm treatments. Given the overall small sample size and also the likely presence of known and unknown biases regarding choice of antiplatelet therapy between groups, larger cohort studies are needed to evaluate SAPT treatment outcomes.
Etiologies and Outcome of Patients with Solid Tumors Admitted to ICU with Acute Respiratory Failure: A Secondary Analysis of the EFRAIM Study
Benguerfi, Soraya , Soares, Márcio , Meert, Anne‐Pascale , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Burghi, Gastón, Kouatchet, Achille, Mokart, Djamel, Louw, Andry Van de , Lemiale, Virginie , group, on behalf of the EFRAIM investigators and Nine-I study, Bauer, Philippe, Martin-Loeches, Ignacio , Dumas, Guillaume , Pène, Frédéric , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , group, on behalf of the EFRAIM investigators and Nine-I study

Mayo Clinic

Respiratory Care | April 18, 2023 | Volume: 68 | Issue: 6 | Pages: 740-748

10.4187/respcare.10604 | PMID 37072164 Get It

BACKGROUND: Acute respiratory failure (ARF) remains the most frequent reason for ICU admission in patients who are immunocompromised. This study reports etiologies and outcomes of ARF in subjects with solid tumors. METHODS: This study was a post hoc analysis of the EFRAIM study, a prospective multinational cohort study that included 1611 subjects who were immunocompromised and with ARF admitted to the ICU. Subjects with solid tumors admitted to the ICU with ARF were included in the analysis. RESULTS: Among the subjects from the EFRAIM cohort, 529 subjects with solid tumors (32.8%) were included in the analysis. At ICU admission, the median (interquartile range) Sequential Organ Failure Assessment score was 5 (3–9). The types of solid tumor were mostly lung cancer ( n = 111, 21%), breast cancer ( n = 52, 9.8%), and digestive cancer ( n = 47, 8.9%). A majority, 379 subjects (71.6%) were full code at ICU admission. The ARF was caused by bacterial or viral infection ( n = 220, 41.6%), extrapulmonary sepsis ( n = 62, 11.7%), or related to cancer or treatment toxicity ( n = 83, 15.7%), or fungal infection ( n = 23, 4.3%). For 63 subjects (11.9%), the ARF etiology remained unknown after an extensive diagnostic workup. The hospital mortality rate was 45.7% ( n = 232/508). Hospital mortality was independently associated with chronic cardiac failure (odds ratio 1.78, 95% CI 1.09–2.92; P = .02), lung cancer (odds ratio 2.50, 95% CI 1.51–4.19; P < .001), day 1 Sequential Organ Failure Assessment score (odds ratio 1.97, 95% CI 1.32-2.96; P < .001). ARF etiologies other than infectious, related to cancer, or treatment toxicity were associated with better outcomes (odds ratio 0.32, 95% CI 0.16–0.61; P < .001). CONCLUSIONS: Infectious diseases remained the most frequent cause of ARF in subjects with solid tumors admitted to the ICU. Hospital mortality was related to severity at ICU admission, previous comorbidities, and ARF etiologies related to non-malignant causes or pulmonary embolism. Lung tumor was also independently associated with higher mortality.
Clinical Features, Non-Contrast CT Radiomic and Radiological Signs in Models for the Prediction of Hematoma Expansion in Intracerebral Hemorrhage
Chen, Zejia , Zhang, Liying , Carrington, André , Thornhill, Rebecca E. , Miguel, Olivier, Auriat, Angela M. , Omid‐Fard, Nima , Hiremath, Shivaprakash B. , Abitbul, Vered Tshemeister, Morotti, Andrea , Casetta, Ilaria , Fainardi, Enrico , Elkabouli, Marah, Talbot, Zoé, Chen, Zejia Frank , Carrington, André M , Thornhill, Rebecca , Hiremath, Shivaprakash , Tshemeister Abitbul, Vered , Dowlatshahi, Dar , Demchuk, Andrew M. , Gladstone, David J. , Huynh, Thien , Melkus, Gerd , Aviv, Richard Ivan

Mayo Clinic

Canadian Association of Radiologists Journal | April 18, 2023 | Volume: 74 | Issue: 4 | Pages: 713-722

10.1177/08465371231168383 | PMID 37070854 Get It

Purpose Rapid identification of hematoma expansion (HE) risk at baseline is a priority in intracerebral hemorrhage (ICH) patients and may impact clinical decision making. Predictive scores using clinical features and Non-Contract Computed Tomography (NCCT)-based features exist, however, the extent to which each feature set contributes to identification is limited. This paper aims to investigate the relative value of clinical, radiological, and radiomics features in HE prediction. Methods Original data was retrospectively obtained from three major prospective clinical trials [“Spot Sign” Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT)NCT01359202; The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT)NCT00810888] Patients baseline and follow-up scans following ICH were included. Clinical, NCCT radiological, and radiomics features were extracted, and multivariate modeling was conducted on each feature set. Results 317 patients from 38 sites met inclusion criteria. Warfarin use (p=0.001) and GCS score (p=0.046) were significant clinical predictors of HE. The best performing model for HE prediction included clinical, radiological, and radiomic features with an area under the curve (AUC) of 87.7%. NCCT radiological features improved upon clinical benchmark model AUC by 6.5% and a clinical & radiomic combination model by 6.4%. Addition of radiomics features improved goodness of fit of both clinical (p=0.012) and clinical & NCCT radiological (p=0.007) models, with marginal improvements on AUC. Inclusion of NCCT radiological signs was best for ruling out HE whereas the radiomic features were best for ruling in HE. Conclusion NCCT-based radiological and radiomics features can improve HE prediction when added to clinical features.
Extracorporeal cardiopulmonary resuscitation: A primer for pharmacists
Brown, Caitlin S. , Wieruszewski, Erin D. , Nei, Scott D. , Vollmer, Nicholas , Mattson, Alicia E , Wieruszewski, Patrick M. , Wieruszewski, Patrick M

Mayo Clinic

American Journal of Health-System Pharmacy | April 18, 2023 | Volume: 80 | Issue: 14 | Pages: 889-898

10.1093/ajhp/zxad077 | PMID 37070401 Get It

Abstract Purpose To describe the use of mechanical circulatory support in the setting of cardiac arrest and summarize pharmacists’ role in extracorporeal cardiopulmonary resuscitation (ECPR). Summary ECPR is increasingly used to reduce morbidity and improve mortality after cardiac arrest. ECPR employs venoarterial ECMO, which provides full circulatory perfusion and gas exchange in both adult and pediatric patients in cardiac arrest. After the emergency medicine team identifies potential candidates for ECPR, the ECMO team is consulted. If deemed a candidate for ECPR by the ECMO team, the patient is cannulated during ongoing standard cardiopulmonary resuscitation. A multidisciplinary team of physicians, nurses, perfusionists, pharmacists, and support staff is needed for successful ECPR. Pharmacists play a vital role in advanced cardiac life support (ACLS) prior to cannulation. Pharmacists intervene to make pharmacotherapy recommendations during ACLS, prepare medications, and administer medications as allowed by institutional and state regulations. Pharmacists also provide pharmacotherapy support in the selection of anticoagulation agents, ongoing vasopressor administration during ECMO cannulation, and the optimization of medication selection in the peri-ECPR period. Conclusion With the growing use of ECPR, pharmacists should be aware of their role in medication optimization during ECPR.